Privately-held Canadian firm AbCellera has announced an expansion to its collaboration with US biotech firm Denali Therapeutics (Nasdaq: DNLI) over the discovery of antibodies as therapies for neurological indications.
As part of the updated deal, AbCellera will generate panels of antibodies for up to eight drug targets nominated by Denali using the Vancouver-based company’s high-throughput, ultra-deep single-cell immune profiling capabilities.
"The field is recognizing the advantages of immune repertoire screening to maximize chances of success"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze